Medina Janaina B, França Vieira E Silva Fábio, Caixeta Rafael Antônio Velôso, de Oliveira Rech Bruna, Perez-Jardón Alba, Padín-Iruegas María Elena, Pérez-Sayáns Mario, Braz-Silva Paulo Henrique, Ortega Karem L
Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain.
ORALRES Group, Health Research Institute of Santiago de Compostela (FIDIS), Santiago de Compostela, Spain.
Eur J Clin Invest. 2025 Aug;55(8):e70068. doi: 10.1111/eci.70068. Epub 2025 May 15.
Torque teno virus (TTV) is not known to cause disease in humans; however, chronic inflammatory conditions and immunosuppression states can favour TTV replication. This study aimed to verify the effectiveness of TTV as an immune biomarker.
The protocol of this review was registered in PROSPERO (CRD42022331049) and performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Thirty-three articles were selected and different groups of patients were assessed. In the solid organ and hematopoietic stem cell transplant groups, most studies reported that TTV viral load (VL) was highly detectable after transplantation and compared to controls, but the association with immune parameters showed conflicting results. In melanoma patients, no statistical difference in TTV VL was identified between susceptible and treatment-resistant patients. In lung cancer patients, viral load increases significantly with disease progression but decreases after chemotherapy. HIV-positive patients showed a higher VL than controls, but an inverse correlation with CD4+ was observed in half of the studies. Although 57.14% of all studies presented a low risk of bias, significant differences were observed between studies, particularly in the choice of the analyzed outcome, the parameter used to evaluate the patient's immune status, the presence of a control group, and the sample collection time points.
Although TTV seems to have the potential to be a promising biomarker of immunosuppression, further high-quality prospective clinical studies are still needed.
目前尚不清楚细小病毒B19(TTV)是否会导致人类疾病;然而,慢性炎症状态和免疫抑制状态可能有利于TTV复制。本研究旨在验证TTV作为免疫生物标志物的有效性。
本综述方案已在国际前瞻性系统评价注册平台(PROSPERO,注册号:CRD42022331049)注册,并按照系统评价和Meta分析的首选报告项目指南进行。
共筛选出33篇文章,并对不同患者组进行了评估。在实体器官移植组和造血干细胞移植组中,大多数研究报告称,移植后TTV病毒载量(VL)高度可检测,与对照组相比,但与免疫参数的关联结果相互矛盾。在黑色素瘤患者中,易感性患者和治疗抵抗性患者之间的TTV VL无统计学差异。在肺癌患者中,病毒载量随疾病进展显著增加,但化疗后降低。HIV阳性患者的VL高于对照组,但在一半的研究中观察到与CD4+呈负相关。尽管所有研究中有57.14%的研究存在低偏倚风险,但研究之间仍存在显著差异,特别是在分析结果的选择、用于评估患者免疫状态的参数、对照组的存在以及样本采集时间点方面。
尽管TTV似乎有潜力成为一种有前景的免疫抑制生物标志物,但仍需要进一步高质量的前瞻性临床研究。